Background: Non-alcoholic fatty liver disease is the fastest growing cause of liver disease in the Western world, yet there is no approved pharmacotherapy. While lifestyle modifications remain the mainstay of treatment, only a proportion of individuals are able to make or sustain them, and so more treatment options are required.
| ME DICATIONS CURRENTLY USE D IN PATIENTS WITH NASH TO TREAT CO-MORBIDITIES

| Dyslipidaemia and hypertension
Dyslipidaemia and hypertension should be managed according to evidence-based guidelines and should reduce cardiovascular morbidity and mortality in patients with NASH. Statins are not only safe in NASH 13 but are also associated with a reduced mortality. 14 Fibrates are synthetic agonists of peroxisome proliferator-activator receptors (PPAR)a, but have not shown benefit in NAFLD outside the management of hypertriglyceridaemia. 15 There are no particularly favoured agents for control of hypertension, although some studies have suggested that angiotensinogen receptor blockers may have additional anti-fibrotic effects, albeit with small participant numbers.
15,16
| Weight management
Orlistat, a gut lipase inhibitor, reduces absorption of dietary fats, and is approved in obesity as an aid to weight loss in conjunction with a hypocaloric diet. 17 Several studies have investigated orlistat in NAFLD, with conflicting results; one study comparing 9 months of hypocaloric diet plus vitamin E with diet plus thrice daily 120 mg orlistat showed improved insulin sensitivity (P<.001), adiponectin (P=.03), steatosis (P=.005), ballooning (P=.04), inflammation (P=.045),
and NAS histology score (P=.009) in those who lost ≤9% body weight, but showed no correlation with the use of orlistat. 18 Conversely, a smaller study comparing the same dose of orlistat with placebo for 6 months in subjects with biopsy confirmed NAFLD showed improved ALT and steatosis by USS in the orlistat group despite similar changes in weight in the two groups 19 ; similar results
were seen in a more recent study following 4 months of treatment. 20 Thus, Orlistat remains a part of weight-loss strategies with insufficient data for its use in NAFLD alone.
| Management of diabetes 2.3.1 | Metformin
Metformin is the first line agent for type 2 diabetes mellitus (T2DM), and reduces the risk of all diabetes-related end-points including microvascular disease, myocardial infarction, large vessel disease, and cardiovascular mortality, in addition to aiding weight loss. 21 Although studies have not demonstrated any improvement in liver enzymes or liver histology, 22 there is epidemiological evidence to suggest it is associated with a reduced incidence of both liver and nonliver malignancies including hepatocellular carcinoma in those with NASH cirrhosis by as much as 7%. 23 ,24
| Glucagon-like peptide-1 and DDPIV inhibitors
Glucagon-like peptide-1 (GLP-1) is a gut-derived hormone analogue that induces insulin secretion, reduces glucagon secretion, suppresses appetite and delays gastric emptying. 25 This class of drugs is licensed for the treatment of diabetes and obesity, improvement of both of which is desirable in patients with NASH. GLP-1 analogues have been shown to improve liver histology in murine models of non-alcoholic steatohepatitis, 26, 27 reduce liver enzymes in patients with T2DM 28, 29 and in clamp studies lead to a reduction in de novo lipogenesis and an increase in fatty acid oxidation in the liver.
29-31
| Liraglutide
Liraglutide is a long-acting GLP-1 analogue which has been shown to induce improvements in peripheral, hepatic and adipose insulin resistance, and reductions in de novo lipogenesis in subjects with 1.8%) in the treated groups, which requires further monitoring and, like liraglutide, gastrointestinal side effects were common, which was the primary reason for discontinuation of treatment. 33 Semaglutide is currently being examined in a phase II trial of patients with NASH and fibrosis (NCT02970942).
Dipeptidyl peptidase-4 (DDP-4) rapidly degrades endogenous GLP-1, and a pilot study of sitagliptin, a selective DDP-4 inhibitor, demonstrated an improvement in liver histology in diabetic patients after 1 year of treatment but included only 15 participants and no control arm. 35 Reduction in liver fat content using magnetic resonance spectroscopy (MRS) has also been demonstrated following 24 weeks of sitagliptin or vildagliptin therapy. 36 However, three subsequent studies have failed to show an effect of sitagliptin treatment on liver fat content, 36 liver enzymes 37 or liver stiffness, 38 and currently its use is reserved for the management of diabetes.
| Sodium glucose co-transporter 2 inhibitors
The sodium glucose co-transporter 2 (SGLT2) is primarily expressed in the renal proximal tubules, and reabsorbs 90% of glucose filtered at the renal glomeruli; inhibition therefore facilitates urinary glucose excretion, and SGLT2 inhibitors are used in diabetes to improve plasma glucose levels and promote weight loss. 39 49, 50 Pooled data from randomised controlled trials showed that UTIs occurred in 3.8% of patients receiving placebo vs 5.9% and 4.4% of those receiving canagliflozin 100 mg and 300 mg once daily respectively. 50 Similar rates of UTIs were reported for dapagliflozin (3.7% for placebo vs 5.7% and 4.3%
for dapagliflozin 5 and 10 mg once daily, respectively), 51 and empagliflozin 10 mg once daily (9.3% vs 7.6% on placebo), although UTI rates for 25 mg empagliflozin were the same as for placebo. Defined as an improvement by 1 or more points in the hepatocellular ballooning score and no increase in fibrosis.
In post-marketing studies, dual-energy X-ray absorptiometry revealed small but statistically significant reductions in bone mineral density at the hip (placebo subtracted changes of À0.9% and À1.2%
for the 100-and 300-mg dose groups respectively) but no other sites. 54 The same risks do not appear to be associated with dapagliflozin or empagliflozin use. 49, 55 Pooled data for canagliflozin from nine clinical trials with a mean treatment time of 85 weeks reported incidence rates for bone fractures of 1.4 and 1.5 per 100 patientyears for those on 100 and 300 mg of canagliflozin, respectively, vs Furthermore, a meta-analysis investigating the effect of vitamin E on the incidence of stroke reported an increase in the relative risk of haemorrhagic stroke by 22%, while the risk of ischaemic stroke was reduced by 10%. 77 Despite the potential benefits in NASH, the risks and benefits of therapy must be carefully discussed with patients in clinical practice.
| DRUGS IN PHASE II/III D EVELOPMENT
The therapeutic landscape for NASH is evolving rapidly with many compounds currently being assessed in phase II/III clinical trials. As detailed in this section these agents are targeting multiple aspects of the pathogenesis of NASH. Table 2 indicates the histological benefits demonstrated in patients with NAFLD and Table 3 shows nonliver related benefits related to drugs used in NAFLD.
| Farnesoid X receptor bile acid axis
The nuclear hormone farnesoid X receptor (FXR) is primarily expressed in the liver, intestines, and kidneys, and has a key role in bile acid synthesis, and also influences carbohydrate and lipid metabolism, and insulin sensitivity. 78 or the different methods used to assess insulin resistance in the two studies it will be an important consideration in the ongoing phase III trial (NCT02548351). Moreover, pruritus was reported in 23% of the treated group, which may be an important consideration for a condition with minimal symptoms. 82 Given the increased risk of cardiovascular morbidity and mortality in patients with NASH, the increased levels of LDL and reduced levels of high-density lipoprotein (HDL)
on OCA therapy are a concern and will require careful attention/ management in future studies. 
| Bile acid sequestrants/transporter inhibitors
Bile acid sequestrants bind bile acids in the gut and can be used to treat dyslipidaemia and hyperphosphataemia, although more recently these agents have been reported to lower blood glucose and increase insulin sensitivity through altered bile acid signalling path- 
79
In another approach, inhibitors of the ileal apical sodium-dependent bile acid transporter (ASBT) have been developed which target bile acid reabsorption in the terminal ileum, and have been demonstrated to improve glycaemic control in diabetic rats, 87 and restore glucose tolerance, reduce hepatic triglyceride and total cholesterol concentrations, as well as improve NAS in HFD-fed mice. 88 An oral inhibitor of ASBT, volixibat (SHP-626), was well tolerated in phase I studies 89 and a phase II trial in patients with NASH is currently enrolling (NCT02787304).
| Hormone signalling
Fibroblast growth factor 21 is a hormone secreted predominantly from the liver, which acts primarily in the fasting state to coordinate carbohydrate and lipid metabolism, enhance insulin sensitivity, decrease triglyceride levels, and cause weight loss, thus ameliorating obesity-associated hyperglycaemia and hyperlipidaemia. 90 In animal models, an FGF-21 analogue (BMS-986036) improved insulin sensitivity, hepatic fat content, and de novo lipogenesis, 91 and a subse- improved NAS scores in mouse models 93 and is currently in a phase II study (NCT02443116) in patients with biopsy-proven NASH.
| Anti-inflammatory and anti-apoptotic agents
Cenicriviroc, a C-C chemokine receptor types 2 and 5 antagonist, has been shown to reduce CD14 which is involved in inflammatory cell activation, and improve the aspartate TOWNSEND AND NEWSOME | 501
Aminotransferase-to-Platelet Count Ratio Index (APRI) and fibrosis-4 scores in patients with HIV. 94 The C-C chemokine receptor Apoptosis signal-regulating kinase 1 is activated by extracellular TNFa, intracellular oxidative or endoplasmic reticulum stress and initiates the p38/JNK pathway, resulting in hepatocyte apoptosis and fibrosis. 97 In animal models ASK1 inhibition reduced hepatic fibrosis, steatosis, and insulin resistance. 98 Two doses of an ASK1
inhibitor, selonsertib, in combination with simtuzumab, or alone, were studied in a phase II trial in patients with NASH and stage 2-3 fibrosis (NCT02466516). Abstract data suggested that high dose selonsertib was effective at reducing fibrosis but did not improve the histological NAS score. Side effects such as headache, nausea, and abdominal pain were more prominent, however, on higher dose combination therapy and are likely to remain a concern in longer term trials. 
| Inhibition of de novo lipogenesis ("Lipid altering")
Aramchol is an arachidic and cholic acid conjugate that was shown to inhibit stearoyl CoA desaturase in vitro and de novo lipogenesis in animal models on high fat diet. 104, 105 A randomised, double-blind, placebo-controlled trial of 60 patients with biopsy-confirmed NAFLD evaluating 100 and 300 mg Aramchol daily for 3 months showed a 12.57%AE22.14% reduction in liver fat content in the 300 mg dose group, compared with an insignificant reduction in the 100 mg group and an increase in those on placebo. However, there were no other significant improvements in metabolic parameters and changes in ALT were minimal. 106 Higher doses of aramchol, 400 and 600 mg, are currently being tested on individuals with NASH in a 52 week phase IIb study investigating their effect on hepatic triglycerides using nuclear MRS, and NAS score as a secondary endpoint (NCT02279524).
Malonyl-CoA is a key regulator of fatty acid metabolism, controlling the balance between de novo lipogenesis and fatty acid oxidation, 107 and ACC is an enzyme that regulates the conversion of malonyl-CoA to Acetyl Co-A. Inhibition of ACC in a murine model of NAFLD increased fatty acid oxidation, reduced lipogenesis and hepatic fat content, and improved insulin sensitivity. 107 A phase I trial using an allosteric inhibitor in obese adults demonstrated a reduction in de novo lipogenesis 108 and the same compound (GS-9676) is being assessed at two dosages for 12 weeks in patients with clinical, radiological or histological NAFLD (NCT02856555). The compound is also being compared with 3 others in another study, as mentioned previously.
The thyroid hormone receptor beta (THR-b) is the predominant liver thyroxine (T4) receptor, through which increased cholesterol metabolism and excretion through bile is mediated. 109 The highly selective (THR-b) agonist MGL-3196 has been developed to target dyslipidaemia but has also been shown to reduce liver steatosis in animal models 110 ; this is now being tested in phase II trials in patients with biopsy proven NASH and ≥10% liver steatosis using change from baseline hepatic fat fraction assessed by MRI-PDFF as a primary outcome (NCT02912260).
| Targeting the gut microbiome
IMM-124e is an IgG-rich extract of bovine colostrum from cows immunised against lipopolysaccharide (LPS), and is believed to reduce exposure of the liver to gut-derived bacterial products and LPS. 111 In phase I studies and pre-clinical data, IMM-124 was found to improve liver enzymes, insulin resistance (OGTT and HgbA1c), and dyslipidaemia (LDL). 111, 112 A phase II RDBPCT is currently evaluating the effects of 24 weeks of IMM-124e in patients with biopsy-proven NASH (NCT02316717).
| Anti-fibrotic agents
Lysyl oxidase like-2 (LOXL2) is one of a family of enzymes involved in modifying the extracellular matrix, promoting cross-linking of cellular collagen, and enhancing fibrosis. 113 Serum LOXL2 levels have been shown to correlate with fibrosis in NAFLD, 114 and an antibody has been developed and studied in a phase IIb clinical trial in patients with NAFLD-related fibrosis; the results are yet to be pub- showed a significant improvement in fibrosis but no improvement in necro-inflammation or ALT. 117 Another combination study involving vitamin E with UDCA for 2 years showed improved serum aminotransferases in the combination group compared to UDCA alone, but no changes in fibrosis. 118 NASH but not fibrosis improved following 48 weeks of rosiglitazone with no additional benefit of metformin or losartan in another combination study. 119 In a 12-month prospective study in patients with type 2 diabetes, both pioglitazone and the combination of pioglitazone and exenatide (synthetic exendin-4) led to significant reductions in liver fat and ALT, and the combination therapy was superior (À60%) compared to pioglitazone alone (À40%), 120 but no combination studies have been carried out in NASH. Targeting fibrosis more directly, Gilead have completed a phase II study in selonsertib (a potent ASK1 inhibitor) and simtuzumab, a LOXL2 antibody, which showed some histological improvement in fibrosis but not NAS score with high dose selonsertib, but little suggestion that the addition of simtuzumab was effective 99 (NCT02466516).
| TREATMENT FOR NASH-WHAT WILL THE MODEL OF CARE BE?
This is an exciting time for pharmacotherapy in NAFLD. Improved understanding of the pathophysiology of NASH has facilitated development of new agents, and evidence is emerging that some already established treatments may have additional benefit. In trials, primary endpoint have focused on improvement in liver-related outcomes, namely NASH resolution and improvement in fibrosis; these goals have been difficult to achieve, likely due to poor efficacy of treatments tested within limited time frames. Whilst the rationale of treatment for NAFLD is to prevent progression to end-stage liver disease, cardiovascular endpoints will be critical in enabling licensing of new drugs.
As NAFLD is an asymptomatic condition with a long natural history, it is difficult to predict how patients will perceive the benefits of therapies with few tangible short-term outcomes. It is likely that drugs will need to be well tolerated and relatively side effect-free if patients are to adhere to medical therapy. Other challenges relate to the duration of treatment in NAFLD and the role of non-invasive markers in determining dose and treatment duration.
Combination therapy is likely to be the utilised in the future, but with results of phase III studies pending, it is difficult to predict which combinations therapies are likely to be most effective. It seems likely that drugs will target different aspects of pathogenesis, that is, an anti-fibrotic in combination with one that targets de novo lipogenesis, or an anti-inflammatory agent paired with one that improves lipid metabolism. There is also the potential for drug therapy to be tailored according to patient needs, that is, using drugs that improve glucose metabolism in those with diabetes, using therapies that promote weight loss in the obese, or anti-inflammatories or anti-fibrotics in those for which these are the predominant histological features.
Notwithstanding the exciting developments of new pharmacological agents, it is important not to lose sight of the importance of modification to not only treat but also to prevent the onset of metabolic syndrome and NAFLD.
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